Compare Amylx Pharmaceuticals Inc (AMLX) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Coursera Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.52 (market cap $2.64B), while Coursera Inc trades at $5.56 (market cap $1.50B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | COUR | |
|---|---|---|
Market Cap | $2.64B | $1.50B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $12.20 |
52-Week Low | $7.82 | $5.09 |
Enterprise Value | $2.39B | $759.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Coursera (COUR) trades at $5.525, down 4.08% today, with a bearish technical signal from moving averages. Revenue grew to $757.5M in 2025, but net losses persist at -$51M. Recent Q2 2026 earnings beat expectations at $0.17 EPS, and the company made a $100M strategic investment in AI education firm LearnVector (Business Wire, July 28, 2026).
The stock offers upside to the $7.70 consensus price target, supported by a majority buy rating from analysts. However, profitability challenges and competitive pressures in online education pose risks. Positive cash flow trends and institutional interest provide a foundation for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
